Vertex should be bought on weakness, says Brean Capital at Brean Capital

theflyonthewall.com

Brean Capital said investors should be opportunistic buyers on any weakness in Vertex shares following its disappointing financial results. The firm said the share price does not reflect the value of the company's cystic fibrosis franchise. Shares remain Buy rated with a $69 price target.

View Comments (0)